Effect of apolipoprotein e polymorphism on statin-induced decreases in plasma lipids and cardiovascular events

Drug Metabolism and Drug Interactions

Volumn 26, Issue 1, 2011, Pages 13-20

  Hubacek, Jaroslav A ^a,b,c   Vrablik, Michal ^d  

^a Cardiovascular Research Center   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

apolipoprotein E; cardiovascular events; cholesterol; gene; interaction; polymorphism; statin; treatment

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ALLELE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; HEART FUNCTION; HEART INFARCTION; HEREDITY; HUMAN; LIPID BLOOD LEVEL; MYALGIA; MYOPATHY; MYOSITIS; PHARMACOGENETICS; REVIEW; RHABDOMYOLYSIS; SMOKING HABIT;

ALLELES; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79956356914     PISSN: 07925077     EISSN: 07925077     Source Type: Journal    
DOI: 10.1515/DMDI.2011.107     Document Type: Review

References (62)

1. Viera AJ, Sheridan SL. Global risk of coronary heart disease: assessment and application. Am Fam Phys 2010;82:265-74.
2. Sadowitz B, Maier KG, Gathan V. Basic science review: statin therapy-Part I: the pleiotropic effects of statins in cardiovascular disease. Vasc Endovasc Surg 2010;44:241-51.
3. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
4. Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf 2011;34:1-19.
5. Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res 2010;7:158-64.
6. Hubacek JA, Bloudickova S, Kubinova R, Pikhart H, Viklicky O, Bobak M. Apolipoprotein E polymorphism in hemodialysed patients and healthy controls. Biochem Genet 2009;47:688-93.
7. Zhang HL, Wu J. Apolipoprotein E4 allele and recurrent pregnancy loss: larger samples are still needed. Am J Reprod Immunol 2010;63:4.
8. Parasuraman R, Greenwood PM, Sunderland T. The apolipo-protein E gene, attention, and brain function. Neuropsychology 2002;16:254-74. (Pubitemid 34280261)
9. de Knijff P, van den Maagdenberg AM, Frants RR, Havekes LM. Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat 1994;4:178-94. (Pubitemid 24319486)
10. Hubacek JA, Pitha J, Stávek P, Schmitz G, Poledne R. Variable expression of hypercholesterolemia in Apolipoprotein E2* (Arg136→Cys) heterozygotes. Physiol Res 2000;49:307-14. (Pubitemid 30646827)
11. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. J Am Med Assoc 2007;298: 1300-11. (Pubitemid 47443344)
12. Gerdes LU, Klausen IC, Sihn I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study population around the world. Genet Epidemiol 1992;9:155-67.
13. Bazrgar M, Karimi M, Fathzadeh M, Senemar S, Peiravian F, Shojaee A, et al. Apolipoprotein E polymorphism in Southern Iran: E4 allele in the lowest reported amounts. Mol Biol Rep 2008;35:495-9.
14. Hayman LL. Abnormal blood lipids: is it environment or is it genes? J Cardiovasc Nurs 2000;14:39-49.
15. Talmud PJ. Gene-environment interaction and its impact on coronary heart disease risk. Nutr Metab Cardiovasc Dis 2007;17:148-52. (Pubitemid 46240792)
16. Smelt AH, de Beer F. Apolipoprotein E and familial dysbeta- lipoproteinemia: clinical, biochemical, and genetic aspects. Semin Vasc Med 2004;4:249-57. (Pubitemid 40094489)
17. Illingworth DR, Bacon S. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. Arteriosclerosis 1989;9:I121-34. (Pubitemid 19046975)
18. De Knijff P, Stalenhoef AF, Mol MJ, Gevers Leuven JA, Smit J, Erkelens DW, et al. Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990;83:89-97. (Pubitemid 20210749)
19. Ojala JP, Helve E, Ehnholm C, Aalto-Setälä K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovasta-tin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991;230:397-405.
20. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipopro-tein E polymorphism. Metabolism 1993;42:895-901. (Pubitemid 23207120)
21. Vohl MC, Szots F, Lelièvre M, Lupien PJ, Bergeron J, Gagné C, et al. Influence of LDL receptor gene mutation and apoE polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholester-olemia. Atherosclerosis 2002;160:361-8. (Pubitemid 34159329)
22. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990;39:150-4. (Pubitemid 20053273)
23. Berglund L, Wiklund O, Eggertsen G, Olofsson SO, Eriksson M, Lindén T, et al. Apolipoprotein E phenotypes in familial hy-percholesterolaemia: importance for expression of disease and response to therapy. J Intern Med 1993;233:173-8. (Pubitemid 23068320)
24. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly de-fined familial hypercholesterolaemia. Pharmacogenet Genomics 2005;15:219-25. (Pubitemid 40569893)
25. Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, et al. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther 2006;11:211-21. (Pubitemid 44536190)
26. Soutar AK. Rare genetic causes of autosomal dominant or recessive hypercholesterolemia. IUBMB Life 2010;62:125-31.
27. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, et al. Effect of apolipoprotein E and A-IV phe-notypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995;113:157-66.
28. Sanllehy C, Casals E, Rodriguez-Villar C, Zambón D, Ojuel J, Ballesta AM, et al. Lack of interaction of apolipoprotein E phe-notype with the lipoprotein response to lovastatin or gemfibro-zil in patients with primary hypercholesterolemia. Metabolism 1998;47:560-5. (Pubitemid 28213116)
29. Ye P, Shang Y, Ding X. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin Med Sci J 2003;18:9-13. (Pubitemid 36402024)
30. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. Pharmacogenetic study of apo-lipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta 2005;362:182-8. (Pubitemid 41597104)
31. Peña R, Lahoz C, Mostaza JM, Jiménez J, Subirats E, Pintó X, et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J Intern Med 2002;251:518-25. (Pubitemid 34535524)
32. Sousa MO, Corbella E, Alía P, Cámara J, Castro MJ, Pintó X, et al. Lack of association between the APOE genotype and the response to statin treatment in patients with acute ischemic episodes. Med Clin (Barc) 2008;130:401-4 (in Spanish). (Pubitemid 351590280)
33. Vossen CY, Hoffmann MM, Hahmann H, Wüsten B, Rothenbacher D, Brenner H. Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program. Clin Pharmacol Ther 2008;84:222-7.
34. Dergunov AD, Perova NV, Visvikis S, Siest G. Time-dependent lipid response on fluvastatin therapy of patients with hyperc-holesterolemia sensitive to apoE phenotype. Vasc Pharmacol 2003;40:237-45. (Pubitemid 38402122)
35. Nestel P, Simons L, Barter P, Clifton P, Colquhoun D, Hamilton-Craig I, et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apoE genotype, lipoprotein(a) and insulin. Atherosclerosis 1997;129:231-9. (Pubitemid 27135325)
36. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cho-lesteraemic response to simvastatin and fluvastatin. Pharmacol Res 2007;55:310-7. (Pubitemid 46518161)
37. Kobayashi T, Homma Y. Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. J Clin Pharmacol 2001;41:1055-8. (Pubitemid 32880132)
38. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000;36:1572-8.
39. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, Stein EM, Corella D, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001;158:183-93. (Pubitemid 32735483)
40. Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Perret B, Ferrières J. Effect of apolipoprotein E alleles and angiotensin- converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction. Am J Cardiol 2003;92:1102-5. (Pubitemid 37329537)
41. Nieminen T, Kähönen M, Viiri LE, Grönroos P, Lehtimäki T. Pharmacogenetics of apolipoprotein E gene during lipid-lower-ing therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 2008;9:1475-86.
42. Watanabe J, Kobayashi K, Umeda F, Yamauchi T, Mimura K, Nakashima N, et al. Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients. Diabetes Res Clin Pract 1993;20:21-7. (Pubitemid 23201811)
43. Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007;9:81-6. (Pubitemid 44921045)
44. Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 2008;18:279-87. (Pubitemid 351367521)
45. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 2005;180:407-15. (Pubitemid 41072913)
46. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006;51:822-6. (Pubitemid 44386828)
47. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5.
48. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8.
49. Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008;1:100-6.
50. Maitland-van der Zee AH, Jukema JW, Zwinderman AH, Hallman DM, De Boer A, Kastelein JJ, et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol 2006;61:327-31. (Pubitemid 44014244)
51. Davies NM, Windmeijer F, Martin RM, Abdollahi MR, Smith GD, Lawlor DA, et al. Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle. Clin Chem 2011;57:502-10.
52. Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G. APOE gene polymorphisms and response to statin therapy among APOE genetic variants. Pharmacogenomics J 2009;9:248-57.
53. Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet 2009;2:173-81.
54. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010;5:e9763.
55. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation 2000;101:1366-71. (Pubitemid 30169856)
56. Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, et al. The effectiveness of hy-droxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics 2002;12:647-53. (Pubitemid 36005674)
57. Chiodini BD, Franzosi MG, Barlera S, Signorini S, Lewis CM, D' Orazio A, et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J 2007;28:1977-83. (Pubitemid 47579537)
58. Ilveskoski E, Lehtimäki T, Laaksonen R, Janatuinen T, Vesalainen R, Nuutila P, et al. Improvement of myocardial blood flow by lipid-lowering therapy with pravastatin is modulated by apolipoprotein E genotype. Scand J Clin Lab Invest 2007;67:723-34. (Pubitemid 350034639)
59. Kashani A, Phillips CO, Foodz JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy. Circulation 2006;114:2788-97.
60. Maitland-van der Zee AH, Stricker BH, Klungel OH, Mantel-Teeuwisse AK, Kastelein JJ, Hofman A, et al. Adherence to and dosing of beta-hydroxy-beta- methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics 2003;13: 219-23. (Pubitemid 36543394)
61. García-Otín AL, Civeira F, Aristegui R, Díaz C, Recalde D, Sol JM, et al. Allelic polymorphism-491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. Eur J Clin Invest 2002;32:421-8. (Pubitemid 36223432)
62. Kajinami K, Takekoshia N, Brousseau DE, Schaefer EJ. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004;177:219-34. (Pubitemid 39505252)